ArticleRevista do Instituto de Medicina Tropical de Sao Paulo2021
Cohort profile update: the main and new findings from the SaMi-Trop Chagas cohort.
Article in Revista do Instituto de Medicina Tropical de Sao Paulo, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- SBC Guideline on the Diagnosis and Treatment of Patients with Cardiomyopathy of Chagas Disease - 2023.Arquivos brasileiros de cardiologia · 2023Guideline
- Chagas Disease in northern Minas Gerais: Clinical and epidemiological features of patients at a pioneering specialized outpatient service.PLoS neglected tropical diseases · 2026Article
- Factors associated with major electrocardiographic abnormalities in chagas disease patients: SaMi-trop cohort.International journal of cardiology. Heart & vasculature · 2026Article
- Implantation of Pacemakers in Patients with Chagas disease: A Case-Control Study of Associated Contextual Factors and Prognosis.Arquivos brasileiros de cardiologia · 2026Article
- Limited transferability of European-based body mass index and blood pressure polygenic scores to admixed Brazilian cohorts.Frontiers in medicine · 2026Article
- Clinical Progression of Cardiac ChronicPathogens (Basel, Switzerland) · 2025Article
- Genetic diversity of Trypanosoma cruzi in individuals with chronic Chagas disease in the Northern Minas Gerais and Vale do Jequitinhonha regions, Minas Gerais, Brazil.PLoS neglected tropical diseases · 2025Article
- Antitrypanosomal therapy for Chagas disease: A single center experience with adverse drug reactions and strategies for enhancing treatment completion.PLoS neglected tropical diseases · 2025Article
- A comparison of artificial intelligence-enhanced electrocardiography approaches for the prediction of time to mortality using electrocardiogram images.European heart journal. Digital health · 2025Article
- IL-17 as a putative hallmark of intense arthralgia and age-related serum immune mediator networks during acute chikungunya fever.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- Evaluation of the properties of WHODAS-12 measurements in individuals with Chagas disease in Brazil.Revista do Instituto de Medicina Tropical de Sao Paulo · 2023Article
- An end is in sight: a perspective on PCR as an endpoint for Chagas disease treatment trials.Frontiers in parasitology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The SaMi-Trop project is a cohort study conducted in 21 municipalities of endemic areas of Chagas disease, including 1,959 patients with chronic Chagas cardiomyopathy. In this article we updated the results of the project, adding information from the second cohort visit. Trypanosoma cruzi-seropositive patients were enrolled from the primary care Telehealth service in Minas Gerais State, Brazil. The eligibility criterium for the second visit was the participation in the baseline evaluation. Of 1,959 participants at the baseline assessment, 1,585 (79.9%) returned after two years for the second evaluation. The mortality rate was 6.7%, but varied from 0.9% to 18.2% when it was stratified by certain clinical characteristics. A lower age-adjusted NT-Pro-BNP level (less than 300) and a prior benznidazole treatment were associated with lower mortality. There was an improvement in most quality of life domain scores. Participants have also reported fewer signs and symptoms and greater use of medication. The second follow-up visit will be complete in Oct 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.